Cargando…

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis

OBJECTIVE: Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to medicinal products (EudraVigilance) for fata...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holmøy, Trygve, Fevang, Børre, Olsen, David Benee, Spigset, Olav, Bø, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689881/ https://www.ncbi.nlm.nih.gov/pubmed/31405369 http://dx.doi.org/10.1186/s13104-019-4507-6

Ejemplares similares

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
por: Myro, Aija Zuleron, et al.
Publicado: (2018)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
por: Sprangers, Ben, et al.
Publicado: (2017)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis
por: Hu, Hannah, et al.
Publicado: (2020)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
por: Holmøy, Trygve, et al.
Publicado: (2017)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up
por: Hyun, Jae-Won, et al.
Publicado: (2019)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
por: Phelps, Richard, et al.
Publicado: (2019)

Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic
por: Jure Hunt, David, et al.
Publicado: (2020)

An Update on Vitamin D and Disease Activity in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2019)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

High‐throughput sequencing of immune repertoires in multiple sclerosis
por: Lossius, Andreas, et al.
Publicado: (2016)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
por: Rauma, Ilkka, et al.
Publicado: (2021)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_so164kpsmhaeq3uv5in4vodfuk